# Atamparib in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07374419/  
OnCo record `nct07374419` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of atamparib escalation levels in non-small-cell lung cancer, run by Nerviano Medical Sciences (Shanghai) Ltd., now recruiting.

## Summary

Atamparib in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07374419 by Nerviano Medical Sciences (Shanghai) Ltd., with 178 participants planned, started 2026-03-18 and due to reach its primary completion in 2028-07-31. Interventions recorded: atamparib escalation levels and atamparib RP2D.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07374419
- Phase: 1/2
- Setting: A Phase Ib/II Study of Atamparib in Patients With Advanced Solid Tumors
- Sponsor: Nerviano Medical Sciences (Shanghai) Ltd.
- Enrolled: 178

## Sources

- ClinicalTrials.gov NCT07374419: https://clinicaltrials.gov/study/NCT07374419

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct07374419.json